Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period.
Maya R SternbergAmelia JohnsonJustice KingAkilah R AliLauren LindeAbiola O AwofesoJodee S BakerNagla S BayoumiSteven BroadwayKatherine BusenCarolyn ChangIris ChengMike CimaAbi CollingwoodVajeera DorabawilaCherie DrenzekAaron FleischauerAshley GentAmanda HartleyLiam HicksMikhail HoskinsAmanda JaraAmanda JonesSaadiah I KhanIshrat Kamal-AhmedSarah KangasFnu KanishkaAlison KleppingerAnna KocharianTomás M LeónRuth Link-GellesB Casey LyonsJohn MasarikAndrea MayDonald McCormickStephanie MeyerLauren MilroyKeeley J MorrisLauren NelsonEnaholo OmoikeKomal PatelMichael PietrowskiMelissa A PikeTamara PilishviliXandy Peterson PompaCharles PowellKevin PraetoriusEli RosenbergAdam SchillerMayra L Smith-CoronadoEmma StanislawskiKyle StrandBuddhi P TilakaratneHailey VestCaleb WiedemanAllison ZaldivarBenjamin SilkHeather M ScobiePublished in: PloS one (2023)
The decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future.